MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414623 | Name: Org 9935

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Org 9935 is a potent, selective PDE3 inhibitor with IC50 of 50 nM.

Chemical Structure

Org 9935
Org 9935
CAS#129425-83-8

Theoretical Analysis

MedKoo Cat#: 414623

Name: Org 9935

CAS#: 129425-83-8

Chemical Formula: C15H16N2O3S

Exact Mass: 304.0882

Molecular Weight: 304.36

Elemental Analysis: C, 59.19; H, 5.30; N, 9.20; O, 15.77; S, 10.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Org 9935; Org9935; Org-9935
IUPAC/Chemical Name
3(2H)-Pyridazinone, 6-(5,6-dimethoxybenzo(b)thien-2-yl)-4,5-dihydro-5-methyl-
InChi Key
KIYDKXDCNSPKQQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H16N2O3S/c1-8-4-14(18)16-17-15(8)13-6-9-5-10(19-2)11(20-3)7-12(9)21-13/h5-8H,4H2,1-3H3,(H,16,18)
SMILES Code
O=C1CC(C)C(C2=CC3=CC(OC)=C(OC)C=C3S2)=NN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 304.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jensen JT, Stouffer RL, Stanley JE, Zelinski MB. Evaluation of the phosphodiesterase 3 inhibitor ORG 9935 as a contraceptive in female macaques: initial trials. Contraception. 2010 Feb;81(2):165-71. doi: 10.1016/j.contraception.2009.09.015. Epub 2009 Nov 6. PMID: 20103457; PMCID: PMC2813210. 2: Jensen JT, Zelinski MB, Stanley JE, Fanton JW, Stouffer RL. The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques. Contraception. 2008 Apr;77(4):303-7. doi: 10.1016/j.contraception.2008.01.003. Epub 2008 Mar 4. PMID: 18342656; PMCID: PMC2505347. 3: Jensen JT, Zelinski-Wooten MB, Schwinof KM, Vance JE, Stouffer RL. The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation during gonadotropin-stimulated ovarian cycles in rhesus macaques. Contraception. 2005 Jan;71(1):68-73. doi: 10.1016/j.contraception.2004.07.007. PMID: 15639077. 4: Gupta A, Pandey AN, Sharma A, Tiwari M, Yadav PK, Yadav AK, Pandey AK, Shrivastav TG, Chaube SK. Cyclic nucleotide phosphodiesterase inhibitors: possible therapeutic drugs for female fertility regulation. Eur J Pharmacol. 2020 Sep 15;883:173293. doi: 10.1016/j.ejphar.2020.173293. Epub 2020 Jul 12. PMID: 32663542. 5: Nicholson CD, Shahid M, Bruin J, Barron E, Spiers I, de Boer J, van Amsterdam RG, Zaagsma J, Kelly JJ, Dent G, et al. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma. J Pharmacol Exp Ther. 1995 Aug;274(2):678-87. PMID: 7636728. 6: El-Metwally M, Shafiee-Nick R, Pyne NJ, Furman BL. The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. Eur J Pharmacol. 1997 Apr 18;324(2-3):227-32. doi: 10.1016/s0014-2999(97)00076-9. PMID: 9145777. 7: Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol. 1998 May;124(1):229-37. doi: 10.1038/sj.bjp.0701833. PMID: 9630364; PMCID: PMC1565378. 8: Challiss RA, Adams D, Mistry R, Nicholson CD. Modulation of spasmogen- stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br J Pharmacol. 1998 May;124(1):47-54. doi: 10.1038/sj.bjp.0701792. PMID: 9630342; PMCID: PMC1565354. 9: Shafiee-Nick R, Pyne NJ, Furman BL. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br J Pharmacol. 1995 Aug;115(8):1486-92. doi: 10.1111/j.1476-5381.1995.tb16641.x. PMID: 8564209; PMCID: PMC1908874. 10: Santing RE, de Boer J, Rohof A, van der Zee NM, Zaagsma J. Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma. Eur J Pharmacol. 2001 Oct 19;429(1-3):335-44. doi: 10.1016/s0014-2999(01)01333-4. PMID: 11698054.